The following is an excerpt from BCC Research Report “Synthetic Biology: Global Markets” by John Bergin.
It is now normal to call biotech and small pharma the innovation engines for the pharmaceutical industry. IPO and ICOs abound, as dollars from venture capital truly flood the ecosystem. In 2018, biopharma investment is having a moment. Any big fluctuation, even a positive one, makes stakeholders nervous. Some of the investors might be tourists—Amazon, Google, Apple, IBM, JP Morgan, Berkshire Hathaway and a half dozen others are new entrants, whose long term goals remain unclear. Particularly disturbing are the health insurance and supply chain changes that make headlines, such as this one.
Urgency for an Antidote to Elephantitis
With each flu season comes a new flu vaccine, but could this cycle be broken? According to a recent article in Scientific American, scientists are moving closer to a universal flu vaccine. Researchers at the University of Southern California are departing from the traditional vaccine, which relies on a cocktail consisting of several strains of killed virus.
“The new vaccine, by contrast, uses a live virus, so it elicits both an antibody response and T cell immunity—at least in lab ferrets and mice,” the article notes.
Topics: Life Sciences